Camilla Krakstad

List of Publications by Citations

124 papers	4,230 citations	31 h-index	62 g-index
139 ext. papers	5,119 ext. citations	7.1 avg, IF	4.65 L-index

#	Paper	IF	Citations
124	Landscape of genomic alterations in cervical carcinomas. *Nature*, **2014**, 506, 371-5	50.4	541
123	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
122	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nature Genetics*, **2013**, 45, 362-70, 370e1-2	36.3	267
121	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. *Molecular Cancer*, **2010**, 9, 135	42.1	203
120	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
119	cAMP effector mechanisms. Novel twists for an old signaling system. *FEBS Letters*, **2003**, 546, 121-6	3.8	150
118	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. *Nature Genetics*, **2016**, 48, 848-55	36.3	135
117	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nature Communications*, **2013**, 4, 1628	17.4	124
116	Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. *Clinical Cancer Research*, **2013**, 19, 1094-105	12.9	110
115	Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. *European Journal of Cancer*, **2013**, 49, 3431-41	7.5	95
114	Ca2+/calmodulin-dependent protein kinase II is required for microcystin-induced apoptosis. *Journal of Biological Chemistry*, **2002**, 277, 2804-11	5.4	93
113	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nature Communications*, **2013**, 4, 1627	17.4	85
112	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. *Molecular Cancer*, **2014**, 13, 223	42.1	72
111	Identification of nine new susceptibility loci for endometrial cancer. *Nature Communications*, **2018**, 9, 3166	17.4	70
110	Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer. *Journal of Magnetic Resonance Imaging*, **2018**, 48, 1637-1647	5.6	57
109	Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. *PLoS ONE*, **2013**, 8, e54873	3.7	56
108	Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. *European Journal of Cancer*, **2014**, 50, 3003-10	7.5	55

107	ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. *Modern Pathology*, **2013**, 26, 428-34	9.8	47
106	Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome. *British Journal of Cancer*, **2012**, 106, 1682-8	8.7	47
105	Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. *Oncotarget*, **2015**, 6, 1327-39	3.3	42
104	PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. *Molecular Oncology*, **2015**, 9, 1694-703	7.9	40
103	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. *Nature Communications*, **2015**, 6, 8234	17.4	40
102	Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. *Cancer Medicine*, **2018**, 7, 1978-1987	4.8	40
101	cAMP protects neutrophils against TNF-alpha-induced apoptosis by activation of cAMP-dependent protein kinase, independently of exchange protein directly activated by cAMP (Epac). *Journal of Leukocyte Biology*, **2004**, 76, 641-7	6.5	40
100	Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. *Cancer Research*, **2014**, 74, 852-61	10.1	36
99	Androgen receptor as potential therapeutic target in metastatic endometrial cancer. *Oncotarget*, **2016**, 7, 49289-49298	3.3	36
98	Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of. *Cancer & Metabolism*, **2019**, 7, 6	5.4	33
97	High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. *Clinical Cancer Research*, **2013**, 19, 2331-41	12.9	33
96	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. *Human Molecular Genetics*, **2015**, 24, 3595-607	5.6	32
95	Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. *PLoS ONE*, **2014**, 9, e90141	3.7	31
94	Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. *Blood*, **2008**, 111, 2866-77	2.2	31
93	Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. *International Journal of Cancer*, **2015**, 136, 1863-73	7.5	30
92	Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 980-7	4	30
91	High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. *PLoS ONE*, **2012**, 7, e52795	3.7	30
90	ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. *Oncotarget*, **2015**, 6, 28440-52	3.3	29

89	Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. *Acta Radiologica*, **2018**, 59, 1010-1017	2	27
88	Evidence of a genetic link between endometriosis and ovarian cancer. *Fertility and Sterility*, **2016**, 105, 35-43.e1-10	4.8	26
87	Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma. *PLoS ONE*, **2015**, 10, e0135220	3.7	26
86	Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. *Oncotarget*, **2014**, 5, 1052-61	3.3	25
85	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1574-84	4	24
84	Nostocyclopeptide-M1: a potent, nontoxic inhibitor of the hepatocyte drug transporters OATP1B3 and OATP1B1. *Molecular Pharmaceutics*, **2011**, 8, 360-7	5.6	24
83	HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. *British Journal of Cancer*, **2018**, 118, 378-387	8.7	24
82	Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. *American Journal of Obstetrics and Gynecology*, **2017**, 217, 432.e1-432.e17	6.4	23
81	Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. *British Journal of Cancer*, **2017**, 117, 840-847	8.7	22
80	Polymorphisms in inflammation pathway genes and endometrial cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 216-23	4	22
79	High visceral fat percentage is associated with poor outcome in endometrial cancer. *Oncotarget*, **2017**, 8, 105184-105195	3.3	22
78	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). *Journal of Genetics and Genome Research*, **2015**, 2,		22
77	Switch in FOXA1 status associates with endometrial cancer progression. *PLoS ONE*, **2014**, 9, e98069	3.7	21
76	High mRNA levels of 17βhydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer. *Molecular and Cellular Endocrinology*, **2017**, 442, 51-57	4.4	20
75	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. *Carcinogenesis*, **2015**, 36, 1341-53	4.6	20
74	Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. *Oncotarget*, **2016**, 7, 69844-69856	3.3	20
73	Patient-Derived Xenograft Models for Endometrial Cancer Research. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	18
72	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. *Genetic Epidemiology*, **2015**, 39, 689-97	2.6	18

71	Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells. *Chemistry and Biology*, **2003**, 10, 609-18		18
70	Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma. *Gynecologic Oncology*, **2015**, 137, 529-37	4.9	17
69	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
68	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. *PLoS ONE*, **2015**, 10, e0128106	3.7	15
67	The cAMP-dependent protein kinase pathway as therapeutic target: possibilities and pitfalls. *Current Topics in Medicinal Chemistry*, **2011**, 11, 1393-405	3	15
66	Whole-Volume Tumor MRI Radiomics for Prognostic Modeling in Endometrial Cancer. *Journal of Magnetic Resonance Imaging*, **2021**, 53, 928-937	5.6	15
65	Blocking 17βhydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach. *Journal of Pathology*, **2018**, 244, 203-214	9.4	15
64	High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. *Gynecologic Oncology*, **2020**, 157, 260-267	4.9	14
63	Off-target effect of the Epac agonist 8-pCPT-2ʹO-Me-cAMP on P2Y12 receptors in blood platelets. *Biochemical and Biophysical Research Communications*, **2013**, 437, 603-8	3.4	14
62	PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. *Scientific Reports*, **2017**, 7, 10240	4.9	14
61	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. *International Journal of Cancer*, **2021**, 148, 307-319	7.5	13
60	Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. *Gynecologic Oncology*, **2015**, 136, 542-8	4.9	12
59	PI3K pathway in gynecologic malignancies. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2013**,	7.1	12
58	Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. *Gynecologic Oncology*, **2018**, 148, 197-203	4.9	12
57	Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. *Gynecologic Oncology*, **2017**, 147, 672-677	4.9	10
56	Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. *Oncotarget*, **2017**, 8, 3881-3894	3.3	10
55	Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients. *Oncotarget*, **2017**, 8, 109018-109026	2.2	10
54	Class I Phosphoinositide 3-Kinase /p110α and /p110β isoforms in Endometrial Cancer. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	10

53	Impact of body mass index and fat distribution on sex steroid levels in endometrial carcinoma: a retrospective study. *BMC Cancer*, **2019**, 19, 547	4.8	9
52	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. *PLoS ONE*, **2018**, 13, e0197561	3.7	9
51	Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. *Clinical Cancer Research*, **2019**, 25, 334-345	12.9	9
50	Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. *PLoS ONE*, **2018**, 13, e0206665	3.7	9
49	Improving response to progestin treatment of low-grade endometrial cancer. *International Journal of Gynecological Cancer*, **2020**, 30, 1811-1823	3.5	8
48	Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. *Molecular Nutrition and Food Research*, **2014**, 58, 2023-35	5.9	8
47	The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. *Human Pathology*, **2021**, 109, 80-91	3.7	8
46	Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer. *European Radiology*, **2020**, 30, 2443-2453	8	7
45	Introduction of aromatic ring-containing substituents in cyclic nucleotides is associated with inhibition of toxin uptake by the hepatocyte transporters OATP 1B1 and 1B3. *PLoS ONE*, **2014**, 9, e94926	3.7	7
44	Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. *Oncotarget*, **2017**, 8, 106989-107001	3.3	7
43	Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. *Cancers*, **2020**, 12,	6.6	7
42	Automated segmentation of endometrial cancer on MR images using deep learning. *Scientific Reports*, **2021**, 11, 179	4.9	7
41	The prognostic value of preoperative FDG-PET/CT metabolic parameters in cervical cancer patients. *European Journal of Hybrid Imaging*, **2018**, 2,	1.7	7
40	Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. *PLoS ONE*, **2019**, 14, e0210585	3.7	6
39	Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. *PLoS Medicine*, **2020**, 17, e1003111	11.6	6
38	Blood Metabolites Associate with Prognosis in Endometrial Cancer. *Metabolites*, **2019**, 9,	5.6	6
37	Blood steroids are associated with prognosis and fat distribution in endometrial cancer. *Gynecologic Oncology*, **2019**, 152, 46-52	4.9	6
36	In vivo MR spectroscopy predicts high tumor grade in endometrial cancer. *Acta Radiologica*, **2018**, 59, 497-505	2	5

35	Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. *Histopathology*, **2012**, 60, 516-9	7.3	5
34	Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. *Oncotarget*, **2017**, 8, 68530-68541	3.3	5
33	Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. *Gynecologic Oncology*, **2020**, 156, 400-406	4.9	5
32	A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease. *British Journal of Cancer*, **2021**, 124, 1690-1698	8.7	5
31	Development of an Image-Guided Orthotopic Xenograft Mouse Model of Endometrial Cancer with Controllable Estrogen Exposure. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	5
30	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. *Human Genetics*, **2021**, 140, 1353-1365	6.3	5
29	Type of vascular invasion in association with progress of endometrial cancer. *Apmis*, **2017**, 125, 1084-1091	3.4	4
28	Poor outcome in hypoxic endometrial carcinoma is related to vascular density. *British Journal of Cancer*, **2019**, 120, 1037-1044	8.7	4
27	Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2018**, 125, 1695-1703	3.7	4
26	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. *Oncotarget*, **2016**, 7, 69097-69110	3.3	4
25	High-Grade Cervical Intraepithelial Neoplasia (CIN) Associates with Increased Proliferation and Attenuated Immune Signaling.. *International Journal of Molecular Sciences*, **2021**, 23,	6.3	4
24	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	3
23	MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer.. *Insights Into Imaging*, **2022**, 13, 1	5.6	3
22	Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. *Oncotarget*, **2017**, 8, 9696-9707	3.3	3
21	Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification. *Cancers*, **2021**, 13,	6.6	3
20	Imaging of Preclinical Endometrial Cancer Models for Monitoring Tumor Progression and Response to Targeted Therapy. *Cancers*, **2019**, 11,	6.6	3
19	Nuclear upregulation of class I phosphoinositide 3-kinase p110β correlates with high 47S rRNA levels in cancer cells. *Journal of Cell Science*, **2021**, 134,	5.3	3
18	An MRI-Based Radiomic Prognostic Index Predicts Poor Outcome and Specific Genetic Alterations in Endometrial Cancer. *Journal of Clinical Medicine*, **2021**, 10,	5.1	3

17	Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. *Human Pathology*, **2019**, 89, 90-98	3.7	2
16	Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. *British Journal of Cancer*, **2020**, 122, 1014-1022	8.7	2
15	Serine/Threonine Protein Phosphatases in Apoptosis **2006**, 151-166		2
14	Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations		2
13	Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. *American Journal of Obstetrics and Gynecology*, **2021**, 225, 407.e1-407.e16	6.4	2
12	Incorporating molecular profiling into endometrial cancer management requires prospective studies. *International Journal of Gynecological Cancer*, **2021**, 31, 944-945	3.5	2
11	Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. *Communications Medicine*, **2021**, 1,		2
10	Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study. *American Journal of Obstetrics and Gynecology*, **2021**,	6.4	2
9	Genomic alterations associated with mutational signatures, DNA damage repair and chromatin remodeling pathways in cervical carcinoma. *Npj Genomic Medicine*, **2021**, 6, 82	6.2	1
8	Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. *Gynecologic Oncology*, **2021**, 160, 396-404	4.9	1
7	Genomic Characterization and Therapeutic Targeting of HPV Undetected Cervical Carcinomas. *Cancers*, **2021**, 13,	6.6	1
6	A radiogenomics application for prognostic profiling of endometrial cancer. *Communications Biology*, **2021**, 4, 1363	6.7	1
5	Cancer awareness in the general population varies with sex, age and media coverage: A population-based survey with focus on gynecologic cancers. *European Journal of Obstetrics, Gynecology and Reproductive Biology*, **2021**, 256, 25-31	2.4	0
4	Feasibility and utility of MRI and dynamic F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer. *Journal of Translational Medicine*, **2021**, 19, 406	8.5	0
3	Interobserver agreement and prognostic impact for MRI-based 2018 FIGO staging parameters in uterine cervical cancer.. *European Radiology*, **2022**, 1	8	0
2	Fully Automatic Whole-Volume Tumor Segmentation in Cervical Cancer. *Cancers*, **2022**, 14, 2372	6.6	0
1	Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. *Pathology Research and Practice*, **2014**, 210, 774-8	3.4	